Search

Author/Creator Modi, Shanu

1. 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients. (9th November 2020)

Authors:
Pusztai, Lajos; Lu, Hailing; Hale, Christopher; Grosse-Wilde, Anne; Specht, Jennifer; Modi, Shanu; Han, Hyo; Cortes, Javier; Oliveira, Mafalda; Garfin, Phillip; Wang, Zejing; Onsum, Matthew
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A198
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. (May 2014)

Authors:
Jhaveri, Komal; Ochiana, Stefan O; Dunphy, Mark PS; Gerecitano, John F; Corben, Adriana D; Peter, Radu I; Janjigian, Yelena Y; Gomes-DaGama, Erica M; Koren, John; Modi, Shanu; Chiosis, Gabriela
Journal:
Expert opinion on investigational drugs
Issue:
Volume 23:Number 5(2014:May)
Page Start:
611
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. (February 2017)

Authors:
Singh, Jasmeet C.; Mamtani, Anita; Barrio, Andrea; Morrow, Monica; Sugarman, Steven; Jones, Lee W.; Yu, Anthony F.; Argolo, Daniel; Smyth, Lilian M.; Modi, Shanu; Schweber, Sarah; Boafo, Camilla; Patil, Sujata; Norton, Larry; Baselga, Jose; Hudis, Clifford A.; Dang, Chau
Journal:
Oncologist
Issue:
Volume 22:Number 2(2017)
Page Start:
139
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. (18th September 2017)

Authors:
Singh, Jasmeet C.; Mamtani, Anita; Barrio, Andrea; Morrow, Monica; Sugarman, Steven; Jones, Lee W.; Yu, Anthony F.; Argolo, Daniel; Smyth, Lilian M.; Modi, Shanu; Schweber, Sarah; Boafo, Camilla; Patil, Sujata; Norton, Larry; Baselga, Jose; Hudis, Clifford A.; Dang, Chau
Journal:
Oncologist
Issue:
Volume 22:Number 2(2017)
Page Start:
139
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up. (2nd January 2019)

Authors:
Wang, Rui; Smyth, Lillian M.; Iyengar, Neil; Chandarlapaty, Sarat; Modi, Shanu; Jochelson, Maxine; Patil, Sujata; Norton, Larry; Hudis, Clifford A.; Dang, Chau T.
Journal:
Oncologist
Issue:
Volume 24:Number 8(2019)
Page Start:
e646
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates. Issue 6 (23rd June 2022)

Authors:
Canestraro, Julia; Hultcrantz, Malin; Modi, Shanu; Hamlin, Paul A.; Shoushtari, Alexander N.; Konner, Jason A.; Tew, William P.; Iyengar, Neil M.; Heinemann, Murk; Abramson, David H.; Francis, Jasmine H.
Journal:
Cornea
Issue:
Volume 41:Issue 6(2022)
Page Start:
792
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗